Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PARK CITY, Utah — In this Healio Video ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

Please provide your email address to receive an email when new articles are posted on . Used in association with the classic VEGF-A antagonists, this new drug could provide complete protection against ...

EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...

New study data indicate that VEGF inhibition suppressed angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system that has antitumor activity, in a mouse model of clear cell ...